Skip to main content
LSL Pharma Group Inc. logo

LSL Pharma Group Inc. — Investor Relations & Filings

Ticker · LSL ISIN · CA50190N1042 TSXV Manufacturing
Open in API
Filings indexed 304 across all filing types
Latest filing 2024-11-22 Regulatory Filings
Country CA Canada
Listing TSXV LSL

About LSL Pharma Group Inc.

https://www.groupelslpharma.com/en

LSL Pharma Group Inc. is an integrated pharmaceutical company focused on the development, manufacturing, and commercialization of specialized life sciences products. The company operates multiple manufacturing facilities dedicated to producing a diverse portfolio, including sterile pharmaceutical products, natural health products (NHPs), cosmetic products, food supplements, and vitamins, often in tablet and capsule formats. LSL Pharma Group functions as a Contract Development and Manufacturing Organization (CDMO) for natural and pharmaceutical segments. The company leverages its integrated capabilities to serve domestic and international markets, including strategic distribution agreements aimed at supplying high-quality pharmaceuticals to alleviate drug shortages in hospital environments.

Recent filings

Filing Released Lang Actions
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a FORM 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate signed by the CEO, certifying the review and fair presentation of the interim financial report and interim MD&A for the period ended September 30, 2024. It explicitly states it is a certification and does not include the actual interim financial statements or substantive financial data. The document length is short (3058 characters) and primarily contains an officer's certification rather than the interim report itself. According to the CERTIFICATION RULE, such documents should be classified as Regulatory Filings (RNS) rather than as an Interim Report (IR).
2024-11-22 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a certification by the Chief Financial Officer regarding the review and fair presentation of the interim financial report and interim MD&A for the period ended September 30, 2024. It is a Form 52-109FV2 certification specific to venture issuers, which is a regulatory attestation rather than the interim report itself. The document does not contain actual financial statements or substantive financial data but rather certifies the accuracy and completeness of such filings. According to the Certification Rule, documents that are primarily officer certifications or attestations, even if referencing interim reports, should be classified as Regulatory Filings (RNS). The document length is 3052 characters, which is relatively short and consistent with a certification letter rather than a full interim report.
2024-11-22 English
Interim MD&A - English.pdf
Management Reports Classification · 95% confidence The document is titled 'Management’s Discussion and Analysis for the three and nine-month periods ended September 30, 2024 and 2023' and contains detailed discussion of financial condition, operating results, non-IFRS financial measures, business strategy, acquisitions, and other management commentary. It references interim periods (quarterly and nine-month periods) and includes substantive financial data and analysis. The document is 15,000 characters long, indicating it is a full report rather than a brief announcement. The content matches the typical characteristics of a Management Discussion and Analysis (MD&A) report, which is classified under Management Reports (MDA). It is not an earnings release (ER) because it contains detailed analysis, not just key highlights. It is not an Annual Report (10-K) because it covers interim periods, not a full fiscal year. Therefore, the correct classification is MDA with high confidence.
2024-11-22 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Condensed Interim Consolidated Financial Statements' for LSL Pharma Group Inc. for the three-month and nine-month periods ended September 30, 2024 and 2023. It contains detailed unaudited financial statements including the statement of financial position, statement of loss and comprehensive loss, statement of changes in shareholders' equity, and statement of cash flows. The document also includes notes to the condensed interim consolidated financial statements, describing the basis of preparation and significant events such as a reverse takeover and acquisitions. The presence of detailed financial data for a period shorter than a full fiscal year, along with the explicit mention of 'interim' and 'unaudited' financial statements, clearly identifies this as an Interim / Quarterly Report. The document is substantive and not merely an announcement or certification, so it is not classified as RPA or RNS. Therefore, the appropriate classification is 'IR' (Interim / Quarterly Report). 9M 2024
2024-11-22 English
News release - English.pdf
Regulatory Filings
2024-11-06 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the first interest payment on convertible debentures issued by LSL Pharma Group Inc. It details the payment amount, interest rate, maturity date, and conversion option of the debentures. There is no financial statement, comprehensive financial data, or detailed analysis present. The document is an update on financing activity related to the company's debt instruments. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is short and it is not a report publication announcement or certification. Hence, the classification is CAP with high confidence.
2024-10-24 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.